Balance Sheet Components (Tables)

12 Months Ended

Dec. 31, 2023

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Schedule of Restricted Cash and Cash Equivalents

A reconciliation of cash, cash equivalents and restricted cash reported within the consolidated balance sheets to the amount reported within the consolidated statements of cash flows is as follows (in thousands):

	December 31,
	2023		2022
Cash and cash equivalents	$	55,816	$	73,456
Restricted cash	5,454		3,954
Total cash, cash equivalents and restricted cash	$	61,270	$	77,410

Schedule of Cash and Cash Equivalents

A reconciliation of cash, cash equivalents and restricted cash reported within the consolidated balance sheets to the amount reported within the consolidated statements of cash flows is as follows (in thousands):

	December 31,
	2023		2022
Cash and cash equivalents	$	55,816	$	73,456
Restricted cash	5,454		3,954
Total cash, cash equivalents and restricted cash	$	61,270	$	77,410

Schedule of Property and Equipment Net

Property and equipment consisted of the following (in thousands):

	December 31,
	2023		2022
Leasehold improvements	$	25,840	$	25,866
Laboratory equipment and office furniture	24,056		23,807
Computer equipment	1,583		1,433
Construction-in-progress	395		284
Total property and equipment, gross	51,874		51,390
Less: accumulated depreciation	(44,841)		(42,894)
Total property and equipment, net	$	7,033	$	8,496

Schedule of Accrued Liabilities

Accrued liabilities consisted of the following (in thousands):

	December 31,
	2023		2022
Clinical trials and research and development costs	$	6,942	$	14,597
Personnel-related costs	6,439		9,181
Accrued expenses	3,257		3,834
Manufacturing costs (1)	461		6,026
Total accrued liabilities	$	17,099	$	33,638

_________________

(1) As of December 31, 2022, the Company recorded an aggregate of $3.0 million for cancellation charges related to the Company's cancellation of its agreement with Lonza Ltd for the Phase 3 manufacturing of NGM621 following Merck's decision to not exercise its option to license NGM621 and the Company's decision not to proceed with further development of NGM621, of which $1.8 million was recorded in accrued manufacturing costs and $1.2 million was included in accounts payable. See Note 5 for additional information.